Jin Medical International Ltd. filings document foreign private issuer reports furnished on Form 6-K, including Nasdaq minimum bid price compliance, shareholder meeting materials, press releases and manufacturing facility updates. The filings identify Jin Medical as a Cayman Islands exempted company with operations centered on rehabilitation medical equipment and wheelchair-related products in China.
Recent regulatory disclosures cover the company’s completed 1-for-20 share consolidation, the reclassification of its ordinary shares into Class A and Class B ordinary shares, and related amendments to its authorized share capital. The record also includes extraordinary general meeting notices, proxy materials, incorporation-by-reference language for an F-3 registration statement, and updates on the Chuzhou facility and Class I Medical Device production license.
Jin Medical International Ltd. completed issuance of 79,762,048 Class A Ordinary Shares to certain third parties on September 24, 2026, in connection with an acquisition transaction and related financial advisory compensation. The issuance diluted Jin Medical Chief Executive Officer and Chairman Erqi Wang’s beneficial ownership from approximately 6.77% to 3.35% and aggregate voting power from approximately 98.12% to 96.15%; Jolly Harmony Enterprises Limited’s beneficial ownership fell from approximately 6.08% to 3.01%. Neither reporting person acquired or disposed of shares. Wang may be deemed to beneficially own 5,306,307 shares, comprising 4,769,057 Class B shares held by Jolly Harmony and 537,250 Class A shares held by Er Pu International Limited; the Class B shares are convertible one-for-one into Class A shares. Both Wang and Jolly Harmony ceased to be beneficial owners of more than 5% of the Class A shares on September 24, 2026.
Jin Medical International Ltd. (ZJYL) closed the transaction under its acquisition agreement on September 24, 2026, for US$159,415,729 in aggregate purchase price. Through Erhua Med, the agreement provides for Jin Medical to obtain contractual control of Huaxia Qiying and the right to receive substantially all of its economic benefits through variable interest entity arrangements. The non-share consideration consists of the HTFX Investment Assets, Changzhou Muchi Investment Assets, Taizhou Muchi Investment Assets, the Kangma Debt and the Kangma Equity.
At closing, Jin Medical issued 71,282,488 Class A ordinary shares as share consideration and 8,479,560 Class A ordinary shares to Veltrion Haskel Holdings Limited and its approved designee, Quinnet Section Limited, for financial advisory services. Immediately afterward, 158,194,533 ordinary shares were issued and outstanding: 153,425,476 Class A and 4,769,057 Class B. The transfer of an 80% equity interest in Zhongjin Kangma Information Technology (Jiangsu) Co., Ltd. was not completed; if incomplete by October 31, 2026, Jin Medical will issue 622,123 Class A ordinary shares as substitute consideration, replacing, not adding to, the Kangma Equity. The issued shares were unregistered and are restricted securities subject to applicable transfer restrictions.
Jin Medical International Ltd. (ZJYL) agreed to acquire contractual control of Huaxia Qiying via PRC variable-interest-entity (VIE) agreements, in a single integrated transaction with aggregate consideration of US$159,415,729.
At closing, Jin Medical plans to issue 71,282,488 Class A ordinary shares as consideration, and may issue an additional 622,123 shares if an 80% equity transfer in Zhongjin Kangma is not completed by October 31, 2026. The Target mainly holds ginseng-related biological assets and technology but does not yet have an established commercial business; the assets are intended to support future commercialization aligned with Jin Medical’s senior-health platform strategy.
The structure relies on multiple VIE contracts (exclusive business cooperation, equity pledge, purchase option and power of attorney) to give Jin Medical effective control and economic benefits without taking legal title to PRC equity. Jin Medical also agreed to pay a financial advisor a 10.0% advisory fee on the transaction value, currently US$15,941,572.90, payable in 8,479,560 shares. The company intends to rely on Nasdaq home-country practice for share-issuance approvals and to issue all new shares in unregistered private placements under Securities Act exemptions.
Jin Medical International Ltd. (ZJYL) received a Schedule 13D from its CEO and chairman, Erqi Wang, and his entities Jolly Harmony Enterprises Limited and Er Pu International Limited, updating their beneficial ownership and voting control following a recapitalization and a related acquisition of Beijing Tongsheng Technology Co., Ltd.
On July 21, 2026, the company repurchased 3,769,057 Class A Ordinary Shares from Jolly Harmony at US$1.641 per share for US$6,185,022.54, then cancelled them and issued the same number of Class B Ordinary Shares to Jolly Harmony at the same price. Each Class B share is convertible into one Class A share and carries 800 votes.
As of July 28, 2026, Mr. Wang is deemed to beneficially own 5,306,307 Class A Ordinary Shares (including 4,769,057 deemed from Class B), or 6.77% of the Class A shares deemed outstanding, but controls about 98.12% of the company’s aggregate voting power, primarily through the high-vote Class B shares held by Jolly Harmony.
Jin Medical International Ltd. (ZJYL) reports that NovastraList Horizon LTD and its sole owner, Chang Gil LEE, beneficially own 7,702,376 Class A ordinary shares. This represents 10.46% of Jin Medical’s Class A ordinary shares, based on 73,663,428 shares outstanding as of July 28, 2026.
NovastraList Horizon LTD holds these shares directly, with sole voting and dispositive power over all 7,702,376 shares. As the 100% owner and sole director of NovastraList Horizon LTD, Chang Gil LEE may be deemed to indirectly beneficially own the same shares, and he has sole voting and dispositive power over them through the entity, while disclaiming beneficial ownership beyond his pecuniary interest.
Jin Medical International Ltd. reported unaudited results for the six months ended March 31, 2026. Total revenue was $8.9 million, down from $9.9 million a year earlier, with gross profit essentially flat at $2.4 million. Net loss attributable to the company was $107,735, or $0.01 per share, similar to the prior-period loss of $89,008, while comprehensive income attributable to the company reached $681,172 due to foreign-currency translation gains. Operating cash flow moved to an outflow of $934,422 from an inflow of $2.6 million. As of March 31, 2026, cash was $9.1 million, short-term investments were $21.0 million, total assets were $55.8 million, and total liabilities were $25.7 million, including $18.0 million of short-term bank loans and a new $2.9 million long-term bank loan.
The company remains highly dependent on a single customer and its subsidiaries, which together accounted for 73.3% of revenue in the period. After the reporting date, Erhua Medical Technology (Changzhou) Co., Ltd. completed a VIE control acquisition of Beijing Tongsheng Technology Co., Ltd., gaining contractual control and rights to substantially all economic benefits of that business. As consideration, Jin Medical issued 64,186,456 Class A ordinary shares to the seller and designees and 6,418,646 Class A shares to a financial advisor, resulting in 78,432,485 ordinary shares outstanding as of July 28, 2026. Shareholders also approved a Third Amended and Restated Memorandum and Articles of Association.
Jin Medical International Ltd. held separate Class A and Class B shareholder meetings, followed by an extraordinary general meeting on July 20, 2026, where shareholders approved significant capital structure and governance changes. As of the June 26, 2026 record date, 6,827,383 Class A ordinary shares and 1,000,000 Class B ordinary shares were outstanding, and 96.99% of total voting power was represented at the extraordinary general meeting.
Shareholders approved increasing authorized share capital to US$15,005,000, including 15,000,000,000 Class A ordinary shares, raising the voting rights of each Class B share from 30 to 800 votes, and adopting a third amended and restated memorandum and articles of association to reflect these changes.
They also approved a related-party share restructuring with Jolly Harmony Enterprises Limited involving the repurchase and cancellation of 3,769,057 Class A shares and the issuance of 3,769,057 Class B shares at a price based on the 90‑day volume weighted average price of the Class A shares, subject to payment and regulatory conditions. In addition, shareholders authorized a VIE-based acquisition of Beijing Tongsheng Technology Co., Ltd., including issuance of 64,186,456 Class A shares at US$1.641 per share as consideration, and approved an advisory engagement with Goldeenridge Ventures Ltd. that provides for potential additional Class A share issuance as compensation, subject to consummation of the acquisition and applicable legal, regulatory and Nasdaq requirements.
Jin Medical International Ltd. reported insider information for director Xue Ning through an initial beneficial ownership statement. The report identifies Ning as a director of Jin Medical but does not list any non-derivative or derivative equity holdings or any insider transactions in the company’s securities as of this filing.
Jin Medical International Ltd. reported that independent director Dr. Jiayuan (James) Tong resigned from the board on July 9, 2026, effective immediately, and stepped down from all committee roles. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.
On July 13, 2026, the board appointed Ning Xue as an independent director, effective July 14, 2026, to fill the vacancy. He becomes chairperson of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees. The board determined he meets Nasdaq and SEC audit committee independence requirements.
Under an Independent Director Agreement, Mr. Xue will serve an initial term from July 14, 2026 to March 27, 2027 and receive US$14,082 in compensation, payable quarterly, plus expense reimbursement. An Indemnification Agreement provides him protection against certain liabilities related to his board service. This governance update is incorporated by reference into the company’s Form F-3 registration statement.
Jin Medical International is amending a prior report mainly to update proxy materials and meeting logistics for July 20, 2026, when Class A holders, Class B holders and all shareholders will vote on major governance and transaction changes.
Key proposals include increasing Class B voting rights from thirty to eight hundred votes per share while Class A stays at one vote, a share capital increase from 45,000,000 to 15,000,000,000 authorized Class A shares, and adopting a new memorandum and articles to reflect these changes. Shareholders will also vote on a related-party repurchase of 3,769,057 Class A shares from Jolly Harmony at a 90‑day VWAP, cancelling them, and issuing 3,769,057 Class B shares to Jolly Harmony at the same VWAP.
Another centerpiece is acquiring contractual control of Beijing Tongsheng Technology via a VIE structure, paying an aggregate US$105,329,974 in the form of 64,186,456 Class A shares at US$1.641 each, plus an expected 6,418,646 Class A shares to Goldeenridge Ventures as advisory compensation. If all steps close, the Seller group would hold about 81.84% of outstanding ordinary shares but only around 1.65% of voting power, while Jolly Harmony would own about 6.08% of shares yet control roughly 98.11% of voting power.